EGFR and non-small cell lung carcinoma: T790M made up 20.3% of all patients in this pooled analysis of more than 1000 non-small-cell lung cancer individuals treated with afatinib, and it ranked second only to 20 insertions and major uncommon mutations, which were primarily seen in patients who had already been initially offered EGFR-TKIs, in frequency.